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ABSTRACT
Introduction: Prostate cancer is the second most lethal cancer in men after lung 
cancer in world. Genetic predisposition is fast emerging as risk factor for prostate 
cancer. The HOXB13 gene is a tumor suppressor gene for prostate cancer and 
other cancers. The present study was conducted to evaluate G84E mutation of 
HOXB13 in patients with prostate cancer in Kurdistan and Kermanshah provinc-
es of Iran. Materials and Methods: DNA was extracted from blood samples of 
cases of Benign Prostatic Hyperplasia and 75 healthy control. The G84E muta-
tion of HOXB13 was determined by direct sequencing. All statistical calculations 
were performed using SPSS version17. Results: DNA sequencing results showed 
that the genotype of this site was GGA in all cases and controls. Conclusion: 
The results of this study showed that the GOXE position of the HOXB13 gene 
was not associated with prostate cancer in selected patients of west Iran. This 
finding showed doesn’t a statistically significant difference in carrier frequency 
highlights the genetic predispositions to prostate cancer with respect to G84E 
mutation of HOXB13 gene. 
INTRODUCTION
Prostate cancer is the second most common male malig-
nancy worldwide (1). Investigating the relationship be-
tween carriers and high risk individuals with prostate can-
cer suggests that there are hereditary components for the 
disease (2-8). Research (GWAS) has identified more than 
75 common alleles that are associated with an increased 
risk of prostate cancer (9-15). Epidemiological studies 
have shown that hereditary factors contribute to the inci-
dence of this disease in 10% of cases, so that men with 
familial history of prostate cancer are more at risk than the 
general population and six to seven years earlier (16). Sev-
eral studies have shown a family history of prostate cancer. 
The main reason for this is the inheritance of the involved 
genes. The first gene site known for prostate cancer is the 
location of a hereditary prostate cancer (Hpc1). After this 
discovery, several other genes are also known, although 
most of them are less important because of their low abun-
dance (16,17). 
In men, increased levels of androgen are associated with 
an increased risk of prostate cancer. The androgen receptor 
gene plays an important role in the incidence and progres-
sion of prostate cancer. Also, the H2D3BI and SRD5A2 
genes, and cyp17, and AR and H2D3B2, have a special 
place in the metabolism of androgens and cell prolifera-
tion in the prostate. Some polymorphisms in these genes 
are associated with an increased risk of prostate cancer. 
The mutation in the androgen receptor is seen in almost all 
cases of prostate cancer, and the treatment options for this 
cancer have been shown to reduce or eliminate testosterone 
binding on the androgen receptor (17,18). The sequence of 
exons in 202 genes in the chromosomal region of the se-
quence of 17q22-22 was associated with a more susceptible 
prostate cancer, resulting in a new discovery in HOXB13 
(19). The HOXB13 gene is a transcription factor, homo-
box involved in the development of normal prostate and the 
main factor in response to androgen. A single-nucleotide 
change in the G84E has been found in the HOXB13 gene, 
which is associated with a 3 to 5-fold increase in the risk 
of prostate cancer (20). A change in the single-nucleotide 
polymorphism of G to A in codon 84 from the HOXB13 
gene has led to a change in the character of this gene as a 
tumor suppressor, according to previous studies (20-22). 
The purpose of the current study is investigating the prev-
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2alence of this single-nucleotide change in a number of pros-
tate cancer Kurdish patients in order to evaluate their role 
in the incidence of prostate cancer.
MATERIALS AND METHODS
Mutation screening
Subjects
In a cross-sectional study conducted from August 2015 to 
June 2017, enrolled 70 men with Benign Prostatic Hyper-
plasia (BPH) and 75 healthy control (ages ranged from 45 
to 78, with an average age of 67 years). The control group 
was selected from men over 60 who had no prostate prob-
lem. They refer to surgical resection in the Department 
of Surgery, the Hospitals of Kurdistan and Kermanshah 
Medical University. The study protocol was approved by 
research committee and all participants signed a written 
consent form. 
DNA extraction
Genomic DNA extraction from peripheral blood samples, 
were carried out using standard extraction protocols (Using 
a Promega DNA purification kit (catalogue no. LA1620). 
The purity of DNA was checked by calculating the ratio of 
OD at A260 to A280 and the integrity was assessed by gel 
electrophoresis on 0.8% agarose gel. DNA concentration 
(μg/ml) = A260 × 50 × dilution factor/1000.
Polymerase Chain Reaction (PCR)
The forward and reverse primers were designed using the 
ABI Primer Express 3.0 Software (Applied Biosystems, 
Foster City, CA, USA). The sequence of the primers used 
were 5’-CGAGCTGGGAGCGATTTA-3(HOXB13-for-
ward) and 5’-AGCTCCAAGTCTCCCTCCTC-3’ 
(HOXB13-reveres). The oligonucleotides of primers were 
synthesized by CinnaGen biotechnology company (Iran). 
Each 25 ul (microliters) PCR reaction contained ~30 ng 
of genomic DNA, 2 ul 10X buffer, 2.5 ul dNTPs, 2.5ul 
Mgcl2, 0.2 ul forward primer, 0.2 ul reverse primer, 0.2 
ul Taq polymerase and 20 ul of deionized dH2O in 25 ul 
reaction mix. The PCR mixture was denatured at 93° C for 
1 min (except the initial denaturing for 3min), annealed for 
1 min at a temperature 51° C and extended at 72° C for1 
min (except the extension for the final cycle for 2min) for 
3o cycles. The presence of the PCR product was investigat-
ed by agarose-gel electrophoresis (1%). DNA marker were 
used for the detection of size of the amplified products. 
The amplified PCR products were purified using KBC pure 
kit (KBCco., Tehran, Iran) according to the manufactur-
er’s instructions, and eluted in 70-140 ul ddH2O prior to 
sequencing.
Direct sequencing
The PCR products sequencing were performed with an ABI 
PRISM Dye Deoxy Terminator Cycle Sequencing Kit and 
an ABI 3100 Genetic Analyzer (Applied Biosystems Inc., 
Warrington, UK) using 5-100 ng of purified PCR products, 
10.4 pmoles of forward or reverse primers, Ready Reaction 
Premix and 1× reaction buffer in a total volume of 20 μl. 
Cycle sequencing reactions were performed in a Primus 96 
cycler (ABI, UK) at 96°C for 60 s ,96°C for 10 s, 50°C 
for 5 s, and 60°C for 4 min for 28 cycles. The prior capil-
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lary electrophoresis, unincorporated dye terminators were 
removed from the extension product by using KBC pure kit 
and DNA was precipitated by using ethanol precipitation. 
The purified extension products were denatured at 95°C for 
5 min and placed on ice for 3 min. The sequencing was 
performed on ABI Genetic Analyzer 3130 and 3130xl ma-
chines (Applied Biosystems Inc., USA) by KBC Co. (KBC 
Co., Tehran, Iran). 
We processed the collected data from the ABI detection sys-
tem using the Sequencing Analyzer version 5.2 software. 
Sequence alignments for the polymorph position in the 
HOXB13 gene read were viewed in the Consed viewer and 
sequence variations was annotated and recorded. The neg-
ative controls were checked for the absence of analyzable 
sequence. Electropherograms were checked for the quali-
ty of sequencing reactions results were therefore checked 
against normal sequence in the Genbank (NCBI) using 
Gene Runner software.
STATISTICAL ANALYSIS 
Genotype distribution and allele frequencies in different 
groups were compared by chi-square analysis. Pearson’s 
correlation and linear regression analysis were carried out to 
determine the correlation between different parameters. A P 
value less than 0.05 was significant. All statistical calculations 
were performed using SPSS for windows, version 17(SPSS 
Inc., Chicago, IL, USA).
RESULTS
In this study, 70 blood samples from prostate cancer pa-
tients ages ranged from 45 to 78, with an average age of 67 
years and 75 blood samples from control group (men over 
60 years old with an average age of 71.20) were collected. 
The findings of polymorphism of GOXE locus of HOXB13 
gene showed that the frequency of healthy controls and pa-
tients according to the status based on the results of DNA 
sequencing of patients and healthy samples, the P-value 
calculation showed that the difference in the frequency of 
healthy and healthy individuals for the polymorph position 
in the HOXB13 gene is not statistically significant at 5% 
level. The number of GGA genotypes in patients and healthy 
individuals is the same. That is, all patients and all healthy 
people showed the GGA genotype. PCR products for G84E 
mutation in HOXB13was shown in figure1.
Fig 1. Electrophoresis of PCR products on agarose (2%).
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Fig 2. DNA sequencing was performed with forwarding 
primer.
(First row: normal sequence, Tier 2: Quality of Stacking, 
Third row: Sequence of samples for Stack sinks, Fourth row: 
sequence of amino acids)
The position of the polymorph in the nucleotide G of the 
GGA sequence, which has been identified on an offline ba-
sis. The amino acid 84 in the exon has a HOXB13 gene poly-
morphism (G84E).
DISCUSSION
The hereditary history of prostate cancer is a major contrib-
utor to this cancer. The history of prostate cancer in the near-
first-degree family increases the likelihood of it. Hereditary 
factors are involved in a small percentage (10%) of cases of 
prostate cancer (22). Studies show that molecular changes 
in HOXB13 gene polymorphism that lead to creating a dif-
ference in main protein is associated with the development 
of prostate cancer (20). Studies have suggested that factors 
such as genetic polymorphism may be indicative of individu-
al differences in the incidence of cancer. Molecular changes, 
including the HOXB13 gene polymorphism, are associated 
with the growth and development of prostate cancer. Poly-
morphism means the occurrence of different types of alleles 
in a gene that has different types. One of the forms of this 
change is codon, followed by a change in the protein. This 
change causes the difference in the main protein function 
(20 - 22). In the present study, the frequency of healthy and 
healthy subjects according to the status of polymorphism of 
the position of GOXE of HOXB13 gene based on DNA se-
quencing results of the patient and healthy samples was ob-
tained by using the P-value test. The difference was found to 
be abundant. The patient and healthy subjects for this poly-
morph position in HOXB13 gene are not statistically signifi-
cant at 5% level. The genotype of all subjects in the control 
and case group was the same as the GGA genotype. Prostate 
cancer is the second most common cancer after skin cancer, 
and the second most lethal cancer after lung cancer in men. 
One in six people suffers from this cancer (21). The past in-
vestigations had showed that prostate cancer seen the lowest 
level in Asian population alike Iranian (22). In several stud-
ies have been conducted on G84E polymorphism HOXB13 
gene and in prostate cancer. For example, in a study in 2013, 
the association of G84E mutations and the risk of prostate 
cancer was studied. In this study, G84E mutation in affect-
ed patients was 42.2% (24). In another study in 2014, the 
G84E mutation was screened on healthy and ill patients in 
Sweden. The results showed that G84E mutation was more 
common in people with prostate cancer who had a familial 
family history and suffered from 35 to 55 years of age. So 
mutation in infected people was 4.6% and in healthy subjects 
was 1.3% (25). In another study in 2013, the association of 
the G84E mutation of the HOXB13 gene with the risk of 
prostate, breast, and colorectal cancer in Finland was inves-
tigated. In this study, the G84E mutation was significantly 
higher among prostate cancer patients with family history 
(4 / 8% versus 1%). In this study, there was no significant 
difference in G84E mutation in breast cancers and family 
colorectal (26). In another study in 2013, the mutation of 
the G84E of the HOXB13 gene and its association with the 
increased risk of prostate cancer were studied with respect to 
different geographical regions and race. The results showed 
that the G84E mutation in HOXB13 differed according to dif-
ferent geographic regions and races, so that in North Europe 
the highest percentage of mutation was 60.1% followed by 
Western Europe 60.0% and in North America, 0.31% G84E 
mutation among individuals Observed (27). Considering the 
result observed in the current study and comparing it with 
other studies, it seems that a greater percentage of patients 
need to be considered to achieve a risk percentage for this 
locus.
CONCLUSION
The results of this study showed that the GOXE position of 
the HOXB13 gene was not associated with prostate cancer in 
selected patients of west Iran. This finding showed doesn’t a 
statistically significant difference in carrier frequency high-
lights the genetic predispositions to prostate cancer with re-
spect to G84E mutation of HOXB13 gene.
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